Literature DB >> 9242428

Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation.

B C Turner1, B G Haffty, L Narayanan, J Yuan, P A Havre, A A Gumbs, L Kaplan, J L Burgaud, D Carter, R Baserga, P M Glazer.   

Abstract

The insulin-like growth factor-I receptor (IGF-IR) plays a critical role in cell growth regulation and transformation. The radiosensitivity of NIH 3T3 fibroblasts overexpressing either wild-type or mutant IGF-IR was examined. High levels of wild-type IGF-IR conferred radioresistance, and mutational analysis revealed that this effect correlated with the transforming capacity but not the mitogenic activity of the receptor. The radioresistant phenotype was reversed when the cells were incubated with antisense oligonucleotides targeted to IGF-IR mRNA, demonstrating that IGF-IR directly influences radioresistance. The clinical significance of these findings was examined in an immunohistochemical analysis of primary breast tumors, revealing that high levels of IGF-IR in tumor samples were highly correlated with ipsilateral breast tumor recurrence (IBTR) following lumpectomy and radiation therapy (P = 0.001). Subgroup analysis revealed that, for early breast tumor relapses (within 4 years of initial breast tumor diagnosis), elevated levels of IGF-IR were strongly associated with IBTR (P = 0.004) but IGF-IR expression was not prognostic for IBTR from breast cancer patients with late relapses (P was not significant). These studies provide evidence for the influence of IGF-IR on cellular radioresistance and response to therapy and raise the possibility that the radiocurability of selected tumors may be improved by pharmaceutical strategies directed toward the IGF-IR.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242428

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  94 in total

Review 1.  IGF and insulin action in the mammary gland: lessons from transgenic and knockout models.

Authors:  D L Hadsell; S G Bonnette
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

2.  Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES.

Authors:  Scott W Blume; Nateka L Jackson; Andra R Frost; William E Grizzle; Oleg D Shcherbakov; Hyoungsoo Choi; Zheng Meng
Journal:  Exp Mol Pathol       Date:  2010-03-15       Impact factor: 3.362

Review 3.  Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.

Authors:  Okkyung Rho; Dae Joon Kim; Karou Kiguchi; John Digiovanni
Journal:  Mol Carcinog       Date:  2010-07-20       Impact factor: 4.784

4.  IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance.

Authors:  Xueyan Zhang; Jiayuan Sun; Huimin Wang; Yuqing Lou; Yanwei Zhang; Huifang Sha; Jiuxian Feng; Baohui Han
Journal:  Tumour Biol       Date:  2013-08-29

5.  IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors.

Authors:  Marc A Becker; Xiaonan Hou; Sean C Harrington; S John Weroha; Sergio E Gonzalez; Kristina A Jacob; Joan M Carboni; Marco M Gottardis; Paul Haluska
Journal:  Clin Cancer Res       Date:  2012-01-27       Impact factor: 12.531

6.  Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

Authors:  Amy S Joehlin-Price; Julie A Stephens; Jianying Zhang; Floor J Backes; David E Cohn; Adrian A Suarez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-18       Impact factor: 4.254

7.  Identification of insulin receptor substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the alpha6beta4 integrin-dependent activation of phosphoinositide 3-OH kinase and promotion of invasion.

Authors:  L M Shaw
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 8.  Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.

Authors:  Jordi Rodon; Victoria DeSantos; Robert Jean Ferry; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

9.  Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGFI receptor.

Authors:  Jennifer A Emond; John P Pierce; Loki Natarajan; Laarni R Gapuz; John Nguyen; Barbara A Parker; Nissi M Varki; Ruth E Patterson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-22       Impact factor: 4.254

10.  Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination.

Authors:  Joanna Trojanek; Thu Ho; Luis Del Valle; Michal Nowicki; Jin Ying Wang; Adam Lassak; Francesca Peruzzi; Kamel Khalili; Tomasz Skorski; Krzysztof Reiss
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.